Elevated Insights

From gene editing to biomanufacturing, learn more about the cell and gene therapy industry from our team of industry-leading experts

Featured Insights

// Oct 2026

Rethinking Release Testing: Building the Analytical Infrastructure for the Next Generation of Advanced Therapies

Adriana Geldart, Head of Technical Services

View Insight

// Sep 2026

Technology, Not Just Biology, Will Deliver the Future of Medicine

Mike Paglia, Chief Technology Officer

View Insight

// Aug 2026

Why the Traditional Approach to Evaluating Gene Editing is Not Your Only Option

By: Larry Lockwood, Chief Commercial Officer

View Insight

// Aug 2026

Partner Case Study: Accelerating CAR T-Cell Therapy Manufacturing for Autoimmune Disease

By: ElevateBio

View Insight

// Oct 2026

Rethinking Release Testing: Building the Analytical Infrastructure for the Next Generation of Advanced Therapies

Adriana Geldart, Head of Technical Services

View Insight

// Oct 2026

How Can Reverse Transcriptase Editing Expand Precision Gene Editing Options?

Drew Kelso Senior Manager, Business Development Gene Editing Services

View Insight

// Oct 2026

How Can Epigenetic Editing Regulate Genes Without Changing DNA?

Ryan Rickels, PhD

View Insight

// Sep 2026

What Drives Cell Therapy Manufacturing Costs, and How Do You Lower Them?

Chris Shumway, M.S. Senior Director, Manufacturing

View Insight

// Sep 2026

Why Isn’t One Assay Enough for Gene Editing Off-Target Safety Assessment?

Allie Crawley, PhD, Associate Director, Computational Biology

View Insight

// Sep 2026

𝘐𝘯 𝘝𝘪𝘷𝘰 Gene Editing Needs Robust Iteration, Not One-Time Optimization

Tyler McCullough, Ph.D

View Insight

// Sep 2026

Technology, Not Just Biology, Will Deliver the Future of Medicine

Mike Paglia, Chief Technology Officer

View Insight

// Aug 2026

Why the Traditional Approach to Evaluating Gene Editing is Not Your Only Option

By: Larry Lockwood, Chief Commercial Officer

View Insight

// Aug 2026

When Should You Engage a Cell and Gene Therapy CDMO? Earlier Than You Think.

By: Yogesh Waghmare, Senior Director, MSAT

View Insight

// Aug 2026

Partner Case Study: Accelerating CAR T-Cell Therapy Manufacturing for Autoimmune Disease

By: ElevateBio

View Insight

// Aug 2026

Targeted Gene Insertion Needs More Than One Tool

By: David Wiley, Director, Nucleic Acid Technology

View Insight

// Aug 2026

How Can AI-Directed Protein Engineering Improve Genomic Medicines?

By, Gavin Ellis, Senior Scientist, Translational Biology

View Insight

Capabilities & Services

Expertise

Elevated Insights

Featured Insights

Rethinking Release Testing: Building the Analytical Infrastructure for the Next Generation of Advanced Therapies

Technology, Not Just Biology, Will Deliver the Future of Medicine

Why the Traditional Approach to Evaluating Gene Editing is Not Your Only Option

Partner Case Study: Accelerating CAR T-Cell Therapy Manufacturing for Autoimmune Disease

Rethinking Release Testing: Building the Analytical Infrastructure for the Next Generation of Advanced Therapies

How Can Reverse Transcriptase Editing Expand Precision Gene Editing Options?

How Can Epigenetic Editing Regulate Genes Without Changing DNA?

What Drives Cell Therapy Manufacturing Costs, and How Do You Lower Them?

Why Isn’t One Assay Enough for Gene Editing Off-Target Safety Assessment?

𝘐𝘯 𝘝𝘪𝘷𝘰 Gene Editing Needs Robust Iteration, Not One-Time Optimization

Technology, Not Just Biology, Will Deliver the Future of Medicine

Why the Traditional Approach to Evaluating Gene Editing is Not Your Only Option

When Should You Engage a Cell and Gene Therapy CDMO? Earlier Than You Think.

Partner Case Study: Accelerating CAR T-Cell Therapy Manufacturing for Autoimmune Disease

Targeted Gene Insertion Needs More Than One Tool

How Can AI-Directed Protein Engineering Improve Genomic Medicines?

Capabilities & Services

Expertise

Elevated Insights

Featured Insights

Rethinking Release Testing: Building the Analytical Infrastructure for the Next Generation of Advanced Therapies

Technology, Not Just Biology, Will Deliver the Future of Medicine

Why the Traditional Approach to Evaluating Gene Editing is Not Your Only Option

Partner Case Study: Accelerating CAR T-Cell Therapy Manufacturing for Autoimmune Disease

Rethinking Release Testing: Building the Analytical Infrastructure for the Next Generation of Advanced Therapies

How Can Reverse Transcriptase Editing Expand Precision Gene Editing Options?

How Can Epigenetic Editing Regulate Genes Without Changing DNA?

What Drives Cell Therapy Manufacturing Costs, and How Do You Lower Them?

Why Isn’t One Assay Enough for Gene Editing Off-Target Safety Assessment?

𝘐𝘯 𝘝𝘪𝘷𝘰 Gene Editing Needs Robust Iteration, Not One-Time Optimization

Technology, Not Just Biology, Will Deliver the Future of Medicine

Why the Traditional Approach to Evaluating Gene Editing is Not Your Only Option

When Should You Engage a Cell and Gene Therapy CDMO? Earlier Than You Think.

Partner Case Study: Accelerating CAR T-Cell Therapy Manufacturing for Autoimmune Disease

Targeted Gene Insertion Needs More Than One Tool

How Can AI-Directed Protein Engineering Improve Genomic Medicines?

Footer